{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Left Eye, No change/improved vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Left Eye, Possible worsened vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Left Eye, Definite worsened vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Right Eye, No change/improved vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Right Eye, Possible worsened vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Right Eye, Definite worsened vision"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any maximum worst-case change from baseline categories are presented for right and left eyes. No change/improved vision is defined as a change from baseline \\<0.12; a possible worsened vision is defined as a change from baseline \\>=0.12 to \\<0.3; a definite worsened vision is defined as a change from baseline \\>=0.3 logMAR score. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores","type":"SECONDARY","unitOfMeasure":"Participants"}